Theranos' Correction Plan For Lab Not Enough To Stop CMS Threat
This article was originally published in Clinica
Executive Summary
Beleaguered laboratory firm Theranos Inc. said late last month that it submitted a correction plan to the Center for Medicare and Medicaid Services to remedy the uncorrected testing deficiencies cited from an inspection by the Medicare agency. But the firm's actions so far have not been enough to stop CMS from proposing sanctions on the company in a March 18 letter, including the potential of barring its California location from operating as a clinical laboratory.
You may also be interested in...
Theranos' Holmes, Balwani Slammed By SEC For 'Massive Fraud'
In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.
Theranos Announces New Hires
Embattled diagnostics developer Theranos hires new VP for regulatory and quality, and a new chief compliance officer.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.